EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Low‐Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial

Hyo-Suk Ahn, Jeong-Cheon Ahn, Jin-Man Cho, Kyung Hee Lim, Seung Hwan Han, Yun-Kyeong Cho, Kye Hun Kim, Soon Jun Hong, Chan Joo Lee, Jin Oh Na, Ki Chul Sung, KyuYoung Choi und 22 weitere

The Journal of Clinical Hypertension · 2026-05 · 28 (5)

DOI: 10.1111/jch.70279 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 13.05.2026. Verfasst von Hyo-Suk Ahn und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul,…. Hauptthemen laut MEDLINE: Amlodipine, Telmisartan, Essential Hypertension, Antihypertensive Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yuhan Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low‐dose single‐pill combinations (SPCs) are gaining recognition as an efficient therapeutic strategy for mild hypertension. However, evidence from randomized controlled trials regarding the efficacy and safety of half‐dose telmisartan/amlodipine SPCs remains limited. In this randomized, double‐blind, active‐controlled phase III trial, patients with essential hypertension [mean sitting systolic blood pressure (MSSBP) ≥ 140 and < 180 mmHg] were allocated to four treatment arms to receive either telmisartan/amlodipine 20/2.5 mg SPC (TEL/AML 20/2.5), or monotherapy with telmisartan 20 mg (TEL 20), amlodipine 2.5 mg (AML 2.5), or telmisartan 40 mg (TEL 40) once daily for 8 weeks. The primary endpoint was the change in MSSBP from baseline to week 8. A gatekeeping approach was used to test the superiority of TEL/AML 20/2.5 over TEL 20 and AML 2.5, followed by non‐inferiority versus TEL 40. At week 8, TEL/AML 20/2.5 showed significantly greater MSSBP reductions compared with TEL 20 [least squares mean (LSM) differences: −5.79 mmHg; p = 0.0003] and AML 2.5 (−8.57 mmHg; p < 0.0001). Non‐inferiority to TEL 40 was established, with an LSM difference of −3.88 mmHg (95% Confidence Interval: −6.67 to −1.09), which met the pre‐specified 3 mmHg margin. The overall incidence of adverse events was 8.05%, with no statistically significant differences between groups. Overall, TEL/AML 20/2.5 SPC provided superior BP‐lowering efficacy compared with TEL 20 and AML 2.5 monotherapies and was non‐inferior to TEL 40. With a comparable safety profile across treatment groups, these findings suggest that TEL/AML 20/2.5 is a practical and effective option for hypertension management. Trial Registration : ClinicalTrials.gov, NCT06052748

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineTelmisartanEssential HypertensionAntihypertensive AgentsHumansDouble-Blind MethodDrug CombinationsFemaleBlood PressureMaleMiddle AgedTreatment OutcomeAgedDose-Response Relationship, Drug

Stichwörter der Autor:innen

hypertensionlow‐dose therapyrandomized controlled trialsingle‐pill combinationtelmisartan/amlodipine

Substanzen

AmlodipineTelmisartanAntihypertensive AgentsDrug Combinationstelmisartan amlodipine combination

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Cardiology, Korea University Ansan Hospital, Ansan, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, Republic of Korea.
  • Division of Cardiology, Dong-A University Hospital, Busan, Republic of Korea.
  • Division of Cardiology, Gachon University Gil Hospital, Incheon, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.

Förderung

  • Yuhan Corporation

Zitieren

APA

Ahn, H. S., Ahn, J. C., Cho, J. M., Lim, K. H., Han, S. H., Cho, Y. K., Kim, K. H., Hong, S. J., Lee, C. J., Na, J. O., Sung, K. C., Choi, K., Kim, S. Y., Kim, D. H., Lee, H. C., Ihm, S. H., Youn, J. C., Choi, J. Y., Kim, S. H., …, & Shin, J. (2026). Low‐Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. The Journal of Clinical Hypertension, 28(5). https://doi.org/10.1111/jch.70279

Vancouver

Ahn HS, Ahn JC, Cho JM, Lim KH, Han SH, Cho YK, et al. Low‐Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. The Journal of Clinical Hypertension. 2026;28(5). doi:10.1111/jch.70279

BibTeX
@article{Ahn2026,
  author = {Ahn, Hyo-Suk and Ahn, Jeong-Cheon and Cho, Jin-Man and Lim, Kyung Hee and Han, Seung Hwan and Cho, Yun-Kyeong and Kim, Kye Hun and Hong, Soon Jun and Lee, Chan Joo and Na, Jin Oh and Sung, Ki Chul and Choi, KyuYoung and Kim, Seok-Yeon and Kim, Dae-Hee and Lee, Han Choel and Ihm, Sang-Hyun and Youn, Jong-Chan and Choi, Ji-Yong and Kim, Sang-Hyun and Kim, Kwang-Il and Sung, Jung-Hoon and Pyun, Wook Bum and Kim, Woo-Shik and Cho, Jung Sun and Lee, Yonggu and Her, Sung-Ho and Cho, Eun Joo and Lee, Eun Mi and Lee, Hae-Young and Yoon, Young Won and Lee, Jang Hoon and Kim, Weon and Rhee, Sang Jae and Shin, Jinho},
  title = {Low‐Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  volume = {28},
  number = {5},
  doi = {10.1111/jch.70279}
}
Kostenlos starten →